9 completed, 3 unknown, 2 recruiting, 1 active not recruiting. 17 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 9, Unknown 3, Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 4 | Completed 2, Not yet recruiting 1, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow GVHD: new trials by email Literature Review of GVHD trials Research Report on GVHD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) Population Vorinostat - GVHD | Phase 2 | Recruiting | Sung Won Choi | 55 | 2026-12-01 | 2026-10-16 |
| Autologous Serum Obtained by a Closed-Circuit Collection Device Autologous Serum 20% - GVHD, Meibomian Gland Dysfunction (Disorder) | Phase 2 | Active not recruiting | GIANCARLO FATOBENE | 16 | 2025-06-20 | 2026-10-21 |
| Safety and Efficacy of Treg Cell in the Treatment of GVHD Regulator T Cells - GVHD | Phase 1 / Phase 2 | Not yet recruiting | Xuzhou Medical University | 20 | 2024-06-01 | 2024-05-13 |
| Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT CD25 treatment, low-dose ATG - GVHD | Phase 2 | Unknown | Wang Xin | 40 | 2024-03-26 | 2024-03-28 |
| MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib Ruxolitinib - GVHD, Acute Stem Cell Transplant Complications | Phase 2 | Unknown | Sichuan University | 62 | 2023-10-01 | 2023-10-10 |
| A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant Photobiomodulation Therapy, Placebo sham device - Graft-Versus-Host Disease, GVHD | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 44 | 2022-12-22 | 2026-11-02 |
| Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD) Apraglutide - GVHD | Phase 2 | Terminated | VectivBio AG | 31 | 2022-05-25 | 2025-10-20 |
| Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation Cyclophosphamide, abatacept, Methotrexate - GVHD, Hematologic Neoplasms | Phase 2 | Completed | Dimitrios Tzachanis, MD PhD | 43 | 2019-11-26 | 2025-10-02 |
| A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD EQ001, EQ001 Placebo - Acute-graft-versus-host Disease, aGVHD | Phase 1 / Phase 2 | Completed | Biocon Limited | 30 | 2019-07-15 | 2026-06-11 |
| High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Bortezomib, Cyclophosphamide - GVHD | Phase 2 | Completed | NYU Langone Health | 23 | 2019-06-20 | 2026-04-23 |
| Itacitinib for Low Risk GVHD Itacitinib - Low Risk Acute Graft-versus-host Disease, Graft-versus-host-disease | Phase 2 | Completed | John Levine | 70 | 2019-03-25 | 2023-02-06 |
| A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD Alpha 1-Antitrypsin - Graft-versus-host-disease, GVHD | Phase 2 | Completed | John Levine | 30 | 2018-08-17 | 2021-07-12 |
| A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression Pacritinib, Sirolimus, Tacrolimus - Graft Vs Host Disease, GVHD | Phase 1 / Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 40 | 2017-06-08 | 2026-04-02 |
| CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT CD45RA-depleted peripheral blood mononuclear cells - Leukemia, Lymphoma | Phase 2 / Phase 3 | Completed | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 150 | 2016-10-01 | 2023-03-16 |
| Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention Panobinostat, Sirolimus, Tacrolimus - Graft Versus Host Disease, GVHD | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 42 | 2016-03-04 | 2021-07-21 |
| Umbilical Cord Blood-derived Mesenchymal Stem Cells for the Treatment of Steroid-refractory Acute or Chronic Graft-versus-host-disease Human umbilical cord blood-derived mesenchymal stem cells - Graft-Versus-Host Disease, GVHD | Phase 1 / Phase 2 | Unknown | Samsung Medical Center | 30 | 2012-01-01 | 2012-03-16 |
| Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation tacrolimus, sirolimus, fludarabine - Graft Versus Host Disease, GVHD | Phase 2 | Completed | Dana-Farber Cancer Institute | 31 | 2006-01-01 | 2014-05-12 |
Graft vs Host Disease (12) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Leukemia (1) · Lymphoma (1) · Meibomian Gland Dysfunction (1) · Myelodysplastic Syndromes (1) · Neoplasms (1) · Opportunistic Infections (1) · Stevens-Johnson Syndrome (1)
Immune System Diseases (12) · Hemic and Lymphatic Diseases (3) · Hematologic Diseases (2) · Bone Marrow Diseases (1) · Chemically-Induced Disorders (1) · Dermatitis (1) · Drug Eruptions (1) · Drug Hypersensitivity (1) · Drug-Related Side Effects and Adverse Reactions (1) · Erythema (1) · Erythema Multiforme (1) · Eye Diseases (1) · Eyelid Diseases (1) · Hypersensitivity (1) · Hypersensitivity, Delayed (1)
Tacrolimus (4) · Sirolimus (3) · Cyclophosphamide (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · Abatacept (1) · Bortezomib (1) · Busulfan (1) · Low-Level Light Therapy (1) · Methotrexate (1) · Panobinostat (1) · Tyrosine Kinase Inhibitors (1) · Vorinostat (1) · alpha 1-Antitrypsin (1) · apraglutide (1) · fludarabine (1)
H. Lee Moffitt Cancer Center and Research Institute (2) · John Levine (2) · Biocon Limited (1) · Dana-Farber Cancer Institute (1) · Dimitrios Tzachanis, MD PhD (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · GIANCARLO FATOBENE (1) · Memorial Sloan Kettering Cancer Center (1) · NYU Langone Health (1) · Samsung Medical Center (1) · Sichuan University (1) · Sung Won Choi (1) · VectivBio AG (1) · Wang Xin (1) · Xuzhou Medical University (1)
United States (11) · China (2) · Brazil (1) · Germany (1) · Portugal (1) · Russia (1) · South Korea (1) · Spain (1)
Ahmad Al-Homsi, MD (1) · Alina Markova, MD (1) · Dimitrios Tzachanis, MD PhD (1) · Divya Koura, MD (1) · Joel Rothman (1) · John Levine, MD (1) · John Levine, MD, MS (1) · Joseph Pidala, M.D. (1) · Larisa Shelikhova, PhD (1) · Lia Perez, M.D. (1) · Mark Vander Lugt, MD, MS (1) · Michael Maschan, PhD (1) · Tomasz Masior (1) · Vincent Ho, MD (1) · Xin Wang (1)
PMID 19539216, PMID 29382747, PMID 33351103, PMID 33753457, PMID 34242388, PMID 35484649, PMID 36095841, PMID 37189240, PMID 40554429
P01CA039542 (1), R01HL133823 (1)